• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

垂体病理学中的免疫组化生物标志物。

Immunohistochemical Biomarkers in Pituitary Pathology.

机构信息

Department of Pathology, Laboratory Medicine Program, University Health Network, 200 Elizabeth Street, 11th Floor, Toronto, Ontario, M5G 2M9, Canada.

Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, M5G 2M9, Canada.

出版信息

Endocr Pathol. 2018 Jun;29(2):130-136. doi: 10.1007/s12022-018-9521-z.

DOI:10.1007/s12022-018-9521-z
PMID:29453601
Abstract

Pituitary pathology is one area of endocrine pathology that is highly dependent on immunohistochemistry. There is a wide range of disorders that occur in and around the sella turcica, and the distinction of tumor-like lesions from neoplasms requires careful evaluation. The diagnosis, prognosis, and predictive features of neoplasms in the sellar region are all dependent on the application and interpretation of biomarkers of cell differentiation, hormonal activity, subcellular morphology, and proliferation. As in hematopathology, the number of biomarkers has increased dramatically and continues to increase. Fortunately, some of the biomarkers provide information that was initially dependent on electron microscopy; therefore, the need for this additional technology has been reduced to only rare unusual tumors. In this review, we provide a simple approach to understanding the importance of the various biomarkers that are used to ensure the correct diagnosis and provide the treating clinicians with tools to guide appropriate patient management and surveillance.

摘要

垂体病理学是内分泌病理学中高度依赖免疫组织化学的一个领域。在蝶鞍及其周围发生着广泛的病变,要区分肿瘤样病变和肿瘤需要仔细评估。鞍区肿瘤的诊断、预后和预测特征都依赖于细胞分化、激素活性、亚细胞形态和增殖的生物标志物的应用和解释。与血液病理学一样,生物标志物的数量已经大大增加,并且还在继续增加。幸运的是,一些生物标志物提供了最初依赖于电子显微镜的信息;因此,对这项额外技术的需求已经减少到只有极少数罕见的肿瘤。在这篇综述中,我们提供了一种简单的方法来理解各种生物标志物的重要性,这些标志物用于确保正确的诊断,并为治疗临床医生提供工具,以指导适当的患者管理和监测。

相似文献

1
Immunohistochemical Biomarkers in Pituitary Pathology.垂体病理学中的免疫组化生物标志物。
Endocr Pathol. 2018 Jun;29(2):130-136. doi: 10.1007/s12022-018-9521-z.
2
Serotonin, ATRX, and DAXX Expression in Pituitary Adenomas: Markers in the Differential Diagnosis of Neuroendocrine Tumors of the Sellar Region.血清素、ATRX 和 DAXX 在垂体腺瘤中的表达:鞍区神经内分泌肿瘤鉴别诊断的标志物。
Am J Surg Pathol. 2017 Sep;41(9):1238-1246. doi: 10.1097/PAS.0000000000000908.
3
Diagnostic and prognostic biomarkers of a sellar melanocytic tumor mimicking pituitary adenoma: Case report and literature review.模仿垂体腺瘤的鞍区黑素细胞肿瘤的诊断和预后生物标志物:病例报告及文献综述
Pathol Res Pract. 2015 Sep;211(9):682-7. doi: 10.1016/j.prp.2015.04.005. Epub 2015 Apr 24.
4
Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms.胃肠道、胰腺、肺和胸腺神经内分泌肿瘤的免疫组织化学生物标志物。
Endocr Pathol. 2018 Jun;29(2):150-168. doi: 10.1007/s12022-018-9522-y.
5
Imaging of sellar and parasellar lesions.鞍区及鞍旁病变的影像学检查
Clin Neurol Neurosurg. 2007 Feb;109(2):111-24. doi: 10.1016/j.clineuro.2006.11.001. Epub 2006 Nov 28.
6
Welcoming the new WHO classification of pituitary tumors 2017: revolution in TTF-1-positive posterior pituitary tumors.欢迎 2017 年世界卫生组织垂体肿瘤分类:TTF-1 阳性垂体后叶肿瘤的革命。
Brain Tumor Pathol. 2018 Apr;35(2):62-70. doi: 10.1007/s10014-018-0311-6. Epub 2018 Mar 2.
7
Immunohistochemical Biomarkers of Adrenal Cortical Neoplasms.肾上腺皮质肿瘤的免疫组化生物标志物。
Endocr Pathol. 2018 Jun;29(2):137-149. doi: 10.1007/s12022-018-9525-8.
8
Immunohistochemical Biomarkers in Diagnosis of Hematolymphoid Neoplasms of Endocrine Organs.免疫组织化学生物标志物在诊断内分泌器官的血液淋巴肿瘤中的应用。
Endocr Pathol. 2018 Jun;29(2):176-188. doi: 10.1007/s12022-018-9533-8.
9
[Incidental findings of expansive processes in the sellar region].[蝶鞍区占位性病变的偶然发现]
Cas Lek Cesk. 2003 Jan 20;142(1):14-8.
10
My approach to pathology of the pituitary gland.我对垂体病理学的研究方法。
J Clin Pathol. 2006 Dec;59(12):1245-53. doi: 10.1136/jcp.2005.031187.

引用本文的文献

1
[Unification of pathomorphological examination of patients with neuroendocrine tumors of the pituitary gland. Controversial issues of the new classification].[垂体神经内分泌肿瘤患者病理形态学检查的统一。新分类的争议问题]
Probl Endokrinol (Mosk). 2023 Nov 14;70(3):31-45. doi: 10.14341/probl13376.
2
Molecular pathology of endocrine gland tumors: genetic alterations and clinicopathologic relevance.内分泌腺肿瘤的分子病理学:遗传改变与临床病理相关性。
Virchows Arch. 2024 Feb;484(2):289-319. doi: 10.1007/s00428-023-03713-4. Epub 2023 Dec 18.
3
Top 10 Nested Pattern Head and Neck Lesions to Notice.

本文引用的文献

1
Epidemiology and biomarker profile of pituitary adenohypophysial tumors.垂体腺垂体肿瘤的流行病学和生物标志物特征。
Mod Pathol. 2018 Jun;31(6):900-909. doi: 10.1038/s41379-018-0016-8. Epub 2018 Feb 12.
2
Corticotroph Pituitary Carcinoma in a Patient With Lynch Syndrome (LS) and Pituitary Tumors in a Nationwide LS Cohort.林奇综合征(LS)患者中的促肾上腺皮质激素垂体癌及全国性LS队列中的垂体肿瘤
J Clin Endocrinol Metab. 2017 Nov 1;102(11):3928-3932. doi: 10.1210/jc.2017-01401.
3
A specific antibody to detect transcription factor T-Pit: a reliable marker of corticotroph cell differentiation and a tool to improve the classification of pituitary neuroendocrine tumours.
十大需要注意的嵌套式头颈部病变。
Head Neck Pathol. 2023 Mar;17(1):119-131. doi: 10.1007/s12105-023-01534-0. Epub 2023 Mar 16.
4
Aggressive nonfunctioning pituitary neuroendocrine tumors.侵袭性无功能性垂体神经内分泌肿瘤。
Brain Tumor Pathol. 2022 Oct;39(4):183-199. doi: 10.1007/s10014-022-00441-6. Epub 2022 Jun 20.
5
Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms.第五版世界卫生组织头颈部肿瘤分类更新:2022 年世界卫生组织头颈部神经内分泌肿瘤分类概述。
Head Neck Pathol. 2022 Mar;16(1):123-142. doi: 10.1007/s12105-022-01435-8. Epub 2022 Mar 21.
6
Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.2022 年世卫组织副神经节瘤和嗜铬细胞瘤分类概述。
Endocr Pathol. 2022 Mar;33(1):90-114. doi: 10.1007/s12022-022-09704-6. Epub 2022 Mar 13.
7
Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification.垂体神经内分泌肿瘤:神经内分泌肿瘤分类的模型。
Mod Pathol. 2021 Sep;34(9):1634-1650. doi: 10.1038/s41379-021-00820-y. Epub 2021 May 21.
8
Significance of Crooke's Hyaline Change in Nontumorous Corticotrophs of Patients With Cushing Disease.库欣病患者无肿瘤性促肾上腺皮质激素细胞中的克劳特透明变性的意义。
Front Endocrinol (Lausanne). 2021 Mar 18;12:620005. doi: 10.3389/fendo.2021.620005. eCollection 2021.
9
Silent Corticotroph Tumor with Adrenocortical Choristoma in an Eleven-year-old Boy.十一岁男孩的无声促肾上腺皮质细胞瘤伴肾上腺皮质包涵瘤。
J Clin Res Pediatr Endocrinol. 2022 Mar 3;14(1):126-130. doi: 10.4274/jcrpe.galenos.2021.2020.0258. Epub 2021 Feb 15.
10
Effect of lncRNA HULC knockdown on rat secreting pituitary adenoma GH3 cells.长链非编码RNA HULC敲低对大鼠分泌性垂体腺瘤GH3细胞的影响。
Braz J Med Biol Res. 2019;52(4):e7728. doi: 10.1590/1414-431X20197728. Epub 2019 Apr 15.
一种用于检测转录因子T-Pit的特异性抗体:促肾上腺皮质激素细胞分化的可靠标志物及改进垂体神经内分泌肿瘤分类的工具
Acta Neuropathol. 2017 Oct;134(4):675-677. doi: 10.1007/s00401-017-1768-9. Epub 2017 Aug 19.
4
Overview of the 2017 WHO Classification of Pituitary Tumors.《2017 年世界卫生组织垂体肿瘤分类概述》。
Endocr Pathol. 2017 Sep;28(3):228-243. doi: 10.1007/s12022-017-9498-z.
5
Epigenetics of pituitary tumors: Pathogenetic and therapeutic implications.垂体瘤的表观遗传学:发病机制和治疗意义。
Mol Cell Endocrinol. 2018 Jul 5;469:70-76. doi: 10.1016/j.mce.2017.07.011. Epub 2017 Jul 12.
6
From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal.从垂体腺瘤到垂体神经内分泌肿瘤(PitNET):国际垂体病理俱乐部提议
Endocr Relat Cancer. 2017 Apr;24(4):C5-C8. doi: 10.1530/ERC-17-0004.
7
Xanthomatous Hypophysitis Is Associated with Ruptured Rathke's Cleft Cyst.黄色瘤性垂体炎与拉克氏囊肿破裂有关。
Endocr Pathol. 2017 Mar;28(1):83-90. doi: 10.1007/s12022-017-9471-x.
8
TFE3-Expressing Perivascular Epithelioid Cell Neoplasm (PEComa) of the Sella Turcica.蝶鞍区表达TFE3的血管周上皮样细胞肿瘤(PEComa)
Endocr Pathol. 2017 Mar;28(1):22-26. doi: 10.1007/s12022-016-9434-7.
9
Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas.静默型 3 型垂体腺瘤并非总是静默的,它们代表分化不良的单型多激素分泌垂体瘤-1 谱系腺瘤。
Mod Pathol. 2016 Feb;29(2):131-42. doi: 10.1038/modpathol.2015.151. Epub 2016 Jan 8.
10
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study.预测第一代生长抑素类似物抵抗的生长激素垂体腺瘤对培高利特反应的因素:免疫组织化学研究。
Eur J Endocrinol. 2016 Feb;174(2):241-50. doi: 10.1530/EJE-15-0832. Epub 2015 Nov 19.